SCHEMBL17536709

SCHEMBL17536709

O=c1[nH]c2ccncc2c2[nH]ncc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.58
FEN1 P39748 1/20 0.44
ACHE P22303 3/20 0.43
DAO P14920 2/20 0.41
CHEK1 O14757 3/20 0.41
CSNK2A1 P68400 2/20 0.41
XDH P47989 1/20 0.40
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
METAP2 P50579 1/20 0.39
KDM5A P29375 2/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37
GRIN2B Q13224 1/20 0.37
GRIN2C Q14957 1/20 0.37
GRIN3A Q8TCU5 1/20 0.37
KDM5C P41229 1/20 0.37
KDM5B Q9UGL1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14796578 0.79 METAP2 (0.62) PARP1DAOCHEK1METAP2GRIN2D
SCHEMBL30273114 0.79 METAP2 (0.62) PARP1DAOCHEK1METAP2GRIN2D
SCHEMBL10134606 0.77 PARP1 (0.79) PARP1FEN1ACHEDAOCSNK2A1
SCHEMBL30866440 0.76 PARP1 (0.57) PARP1FEN1ACHEDAOCHEK1
SCHEMBL30766035 0.76 PARP1 (0.62) PARP1FEN1ACHEDAOCHEK1
SCHEMBL30866441 0.76 PARP1 (0.57) PARP1FEN1ACHEDAOCHEK1
SCHEMBL30704720 0.74 PARP1 (1.00) PARP1FEN1ACHECHEK1CSNK2A1
SCHEMBL1478179 0.74 PARP1 (1.00) PARP1FEN1ACHECHEK1CSNK2A1
SCHEMBL9533317 0.73 PARP1 (0.62) PARP1FEN1ACHEDAOCHEK1
SCHEMBL2411557 0.72 AURKA (0.60) PARP1FEN1DAOXDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856257-B2 Pyrazolonaphthyridinone derivatives as MetAP2 inhibitors (methionine aminopeptidase type-2) SANOFI (FR) 2018-01-02 US disclosed
EP-2978764-B1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) SANOFI SA (FR) 2017-04-19 EP disclosed
US-20160060265-A1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) SANOFI (FR) 2016-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160060265-A1 PYRAZOLONAPHTHYRIDINONE DERIVATIVES AS METAP2 INHIBITORS (METHIONINE AMINOPEPTIDASE TYPE-2) METAP2, METAP1, XPNPEP2 PARP1 2711/4885FEN1 785/4885ACHE 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.